PATENT CLAIM ANALYSIS

Application Number: 15946505
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["435", "188000"]

Abstract:
The present disclosure relates to compositions and methods for treating Sanfilippo syndrome (also known as Sanfilippo disease type D, Sanfilippo D, mucopolysaccharidosis type IIID, MPS IIID). The method can entail injecting to the spinal fluid of a MPS IIID patient an effective amount of a composition comprising a recombinant human acetylglucosamine-6-sulfatase (GNS) protein comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and having the enzymatic activity of the human GNS protein. The composition can be provided in an artificial cerebrospinal fluid. About 1 mg to about 100 mg of the recombinant polypeptide may be administered to the patient once every 2 weeks to 6 months.

Claim (Index 10):
The method of  claim 5 , wherein the artificial cerebrospinal fluid comprises:\n about 140-160 mEq/l sodium, about 3.5-4.5 mEq/l potassium, about 2.5-3 mEq/l calcium, about 2-3 mEq/l magnesium, about 120-140 mEq/l chloride, about 1-2 mEq/l phosphate, about 18-25 mEq/l bicarbonate, and about 2-3 mEq/l sulfate.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 91.0
- Lexical Diversity: 1.7125
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14573907', '13188907', '14281538', '12629029', '14924405']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6304079615761026
- 35 USC 102 Novelty (BERT): 0.5040821159861292
- Combined Prediction Score: 0.6177753770171053
- Mean Citation Score: 239.725566
- Max Citation Score: 242.75977000000003
- Similarity Product: 156.0750721053392

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test